New research suggests that a single administration of spinal segment-targeted gene therapy may provide a long-lasting strategy for reducing muscle spasticity caused by spinal cord injury and potentially other neurological conditions associated with abnormal muscle tone.
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
